Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
23 02 2021
Historique:
received: 14 01 2021
revised: 17 02 2021
accepted: 19 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 13 3 2021
Statut: epublish

Résumé

Since December 2019, SARS-CoV-2 infection has been still rapidly spreading, resulting in a pandemic, followed by an increasing number of cases in countries throughout the world. The severity of the disease depends on the patient's overall medical condition but no appropriate markers are available to establish the prognosis of the patients. We performed a 16S rRNA gene sequencing, revealing an altered composition of the nasal/oropharyngeal (NOP) microbiota in 21 patients affected by COVID-19, paucisymptomatic or in an Intensive Care Unit (ICU), as compared to 10 controls negative for COVID-19 or eight affected by a different Human Coronavirus (HKU, NL63 and OC43). A significant decrease in Chao1 index was observed when patients affected by COVID-19 (in ICU) were compared to paucisymptomatic. Furthermore, patients who were in ICU, paucisymptomatic or affected by other Coronaviruses all displayed a decrease in the Chao1 index when compared to controls, while Shannon index significantly decreased only in patients under ICU as compared to controls and paucisymptomatic patients. At the phylum level, Deinococcus-Thermus was present only in controls as compared to SARS-CoV-2 patients admitted to ICU, paucisymptomatic or affected by other coronaviruses. Candidatus Saccharibacteria (formerly known as TM7) was strongly increased in negative controls and SARS-CoV-2 paucisymptomatic patients as compared to SARS-CoV-2 ICU patients. Other modifications were observed at a lower taxonomy level. Complete depletion of Bifidobacterium and Clostridium was exclusively observed in ICU SARS-CoV-2 patients, which was the only group characterized by the presence of Salmonella, Scardovia, Serratia and Pectobacteriaceae. In conclusion, our preliminary results showed that nasal/oropharyngeal microbiota profiles of patients affected with SARS-CoV-2 may provide valuable information in order to facilitate the stratification of patients and may open the way to new interventional strategies in order to ameliorate the outcome of the patients.

Identifiants

pubmed: 33672177
pii: ijerph18042174
doi: 10.3390/ijerph18042174
pmc: PMC7926517
pii:
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : Ricerca Corrente Linea 1 COVID-2020-12371817
Organisme : European Commission - Horizon 2020
ID : EU project 101003544
Organisme : CoNVat; EU
ID : project 101003551
Organisme : EXSCALATE4CoV; EU project
ID : EU project 202012371675 EU project 12371675
Organisme : EXCALATE4CoV;
ID : EU project 101005075-KRONO
Organisme : the European Virus Archive - GLOBAL
ID : grants no. 653316 and no. 871029
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 2019 - ID. 23006

Références

Front Immunol. 2019 Jul 04;10:1551
pubmed: 31333675
Life (Basel). 2020 Dec 11;10(12):
pubmed: 33322584
J Transl Med. 2020 Apr 6;18(1):154
pubmed: 32252784
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1104-1115
pubmed: 27135599
Science. 2011 Oct 14;334(6053):249-52
pubmed: 21998395
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
Front Oncol. 2020 May 22;10:679
pubmed: 32523887
Nat Rev Microbiol. 2017 May;15(5):259-270
pubmed: 28316330
PLoS Pathog. 2012;8(5):e1002681
pubmed: 22615558
Lett Appl Microbiol. 2010 Jun 1;50(6):597-602
pubmed: 20438620
Genome Med. 2016 Apr 20;8(1):42
pubmed: 27098727
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Diabetes Metab Syndr. 2020 May - Jun;14(3):251-254
pubmed: 32247213
Int J Environ Res Public Health. 2019 Oct 23;16(21):
pubmed: 31652705
Front Med. 2020 Apr;14(2):126-135
pubmed: 32240462
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Expert Rev Anti Infect Ther. 2017 Jul;15(7):703-711
pubmed: 28661199
Microbiome. 2018 May 22;6(1):92
pubmed: 29789015
Health Sci Rep. 2018 May 09;1(6):e47
pubmed: 30623080
Microb Cell. 2018 May 07;5(5):215-219
pubmed: 29796386

Auteurs

Martina Rueca (M)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Andrea Fontana (A)

Biostatistics Unit Fondazione-IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo , Italy.

Barbara Bartolini (B)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Pierluca Piselli (P)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Antonio Mazzarelli (A)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Massimiliano Copetti (M)

Biostatistics Unit Fondazione-IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo , Italy.

Elena Binda (E)

Cancer Stem Cell Unit, ISBReMIT Fondazione-IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo, Italy.

Francesco Perri (F)

Gastroenterology Unit Fondazione-IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo, Italy.

Cesare Ernesto Maria Gruber (CEM)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Emanuele Nicastri (E)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Luisa Marchioni (L)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Giuseppe Ippolito (G)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Maria Rosaria Capobianchi (MR)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Antonino Di Caro (A)

National Institute for Infectious Diseases "L. Spallanzani", IRCCS, 00149 Rome, Italy.

Valerio Pazienza (V)

Gastroenterology Unit Fondazione-IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH